img

Global Polycystic Ovary Syndrome Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Polycystic Ovary Syndrome Market Research Report 2024

According to MRAResearch’s new survey, global Polycystic Ovary Syndrome market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Polycystic Ovary Syndrome market research.
Key companies engaged in the Polycystic Ovary Syndrome industry include Abbott Laboratories, Addex therapeutics, Himalaya, Astellas Pharma, AstraZeneca, Ava Science, Bayer, Bristol-Myers Squibb and Theralogix, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Polycystic Ovary Syndrome were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Polycystic Ovary Syndrome market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Polycystic Ovary Syndrome market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Abbott Laboratories
Addex therapeutics
Himalaya
Astellas Pharma
AstraZeneca
Ava Science
Bayer
Bristol-Myers Squibb
Theralogix
Ferring Pharmaceuticals
Teva Pharmaceutical
GSK
Sneha Natura
Jarrow Formulas
Merck
Millendo Therapeutics
MyOva
Novartis
Ogeda
PCOS Diva
Pharmasure
Salveo Lifecare
Segment by Type
Diuretics
Insulin sensitizing agents
Antiandrogens
Anti-depressants
Ornithine decarboxylase inhibitors

Segment by Application


Hospital pharmacies
Drug stores
Retail pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Polycystic Ovary Syndrome report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Polycystic Ovary Syndrome Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Diuretics
1.2.3 Insulin sensitizing agents
1.2.4 Antiandrogens
1.2.5 Anti-depressants
1.2.6 Ornithine decarboxylase inhibitors
1.3 Market by Application
1.3.1 Global Polycystic Ovary Syndrome Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospital pharmacies
1.3.3 Drug stores
1.3.4 Retail pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Polycystic Ovary Syndrome Market Perspective (2018-2033)
2.2 Polycystic Ovary Syndrome Growth Trends by Region
2.2.1 Global Polycystic Ovary Syndrome Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Polycystic Ovary Syndrome Historic Market Size by Region (2018-2023)
2.2.3 Polycystic Ovary Syndrome Forecasted Market Size by Region (2024-2033)
2.3 Polycystic Ovary Syndrome Market Dynamics
2.3.1 Polycystic Ovary Syndrome Industry Trends
2.3.2 Polycystic Ovary Syndrome Market Drivers
2.3.3 Polycystic Ovary Syndrome Market Challenges
2.3.4 Polycystic Ovary Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Polycystic Ovary Syndrome Players by Revenue
3.1.1 Global Top Polycystic Ovary Syndrome Players by Revenue (2018-2023)
3.1.2 Global Polycystic Ovary Syndrome Revenue Market Share by Players (2018-2023)
3.2 Global Polycystic Ovary Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Polycystic Ovary Syndrome Revenue
3.4 Global Polycystic Ovary Syndrome Market Concentration Ratio
3.4.1 Global Polycystic Ovary Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Polycystic Ovary Syndrome Revenue in 2022
3.5 Polycystic Ovary Syndrome Key Players Head office and Area Served
3.6 Key Players Polycystic Ovary Syndrome Product Solution and Service
3.7 Date of Enter into Polycystic Ovary Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Polycystic Ovary Syndrome Breakdown Data by Type
4.1 Global Polycystic Ovary Syndrome Historic Market Size by Type (2018-2023)
4.2 Global Polycystic Ovary Syndrome Forecasted Market Size by Type (2024-2033)
5 Polycystic Ovary Syndrome Breakdown Data by Application
5.1 Global Polycystic Ovary Syndrome Historic Market Size by Application (2018-2023)
5.2 Global Polycystic Ovary Syndrome Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Polycystic Ovary Syndrome Market Size (2018-2033)
6.2 North America Polycystic Ovary Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Polycystic Ovary Syndrome Market Size by Country (2018-2023)
6.4 North America Polycystic Ovary Syndrome Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Polycystic Ovary Syndrome Market Size (2018-2033)
7.2 Europe Polycystic Ovary Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Polycystic Ovary Syndrome Market Size by Country (2018-2023)
7.4 Europe Polycystic Ovary Syndrome Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Polycystic Ovary Syndrome Market Size (2018-2033)
8.2 Asia-Pacific Polycystic Ovary Syndrome Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Polycystic Ovary Syndrome Market Size by Region (2018-2023)
8.4 Asia-Pacific Polycystic Ovary Syndrome Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Polycystic Ovary Syndrome Market Size (2018-2033)
9.2 Latin America Polycystic Ovary Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Polycystic Ovary Syndrome Market Size by Country (2018-2023)
9.4 Latin America Polycystic Ovary Syndrome Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Polycystic Ovary Syndrome Market Size (2018-2033)
10.2 Middle East & Africa Polycystic Ovary Syndrome Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Polycystic Ovary Syndrome Market Size by Country (2018-2023)
10.4 Middle East & Africa Polycystic Ovary Syndrome Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Polycystic Ovary Syndrome Introduction
11.1.4 Abbott Laboratories Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 Addex therapeutics
11.2.1 Addex therapeutics Company Detail
11.2.2 Addex therapeutics Business Overview
11.2.3 Addex therapeutics Polycystic Ovary Syndrome Introduction
11.2.4 Addex therapeutics Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.2.5 Addex therapeutics Recent Development
11.3 Himalaya
11.3.1 Himalaya Company Detail
11.3.2 Himalaya Business Overview
11.3.3 Himalaya Polycystic Ovary Syndrome Introduction
11.3.4 Himalaya Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.3.5 Himalaya Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Detail
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Polycystic Ovary Syndrome Introduction
11.4.4 Astellas Pharma Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.4.5 Astellas Pharma Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Polycystic Ovary Syndrome Introduction
11.5.4 AstraZeneca Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.5.5 AstraZeneca Recent Development
11.6 Ava Science
11.6.1 Ava Science Company Detail
11.6.2 Ava Science Business Overview
11.6.3 Ava Science Polycystic Ovary Syndrome Introduction
11.6.4 Ava Science Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.6.5 Ava Science Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Polycystic Ovary Syndrome Introduction
11.7.4 Bayer Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.7.5 Bayer Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Polycystic Ovary Syndrome Introduction
11.8.4 Bristol-Myers Squibb Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Theralogix
11.9.1 Theralogix Company Detail
11.9.2 Theralogix Business Overview
11.9.3 Theralogix Polycystic Ovary Syndrome Introduction
11.9.4 Theralogix Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.9.5 Theralogix Recent Development
11.10 Ferring Pharmaceuticals
11.10.1 Ferring Pharmaceuticals Company Detail
11.10.2 Ferring Pharmaceuticals Business Overview
11.10.3 Ferring Pharmaceuticals Polycystic Ovary Syndrome Introduction
11.10.4 Ferring Pharmaceuticals Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.10.5 Ferring Pharmaceuticals Recent Development
11.11 Teva Pharmaceutical
11.11.1 Teva Pharmaceutical Company Detail
11.11.2 Teva Pharmaceutical Business Overview
11.11.3 Teva Pharmaceutical Polycystic Ovary Syndrome Introduction
11.11.4 Teva Pharmaceutical Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.11.5 Teva Pharmaceutical Recent Development
11.12 GSK
11.12.1 GSK Company Detail
11.12.2 GSK Business Overview
11.12.3 GSK Polycystic Ovary Syndrome Introduction
11.12.4 GSK Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.12.5 GSK Recent Development
11.13 Sneha Natura
11.13.1 Sneha Natura Company Detail
11.13.2 Sneha Natura Business Overview
11.13.3 Sneha Natura Polycystic Ovary Syndrome Introduction
11.13.4 Sneha Natura Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.13.5 Sneha Natura Recent Development
11.14 Jarrow Formulas
11.14.1 Jarrow Formulas Company Detail
11.14.2 Jarrow Formulas Business Overview
11.14.3 Jarrow Formulas Polycystic Ovary Syndrome Introduction
11.14.4 Jarrow Formulas Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.14.5 Jarrow Formulas Recent Development
11.15 Merck
11.15.1 Merck Company Detail
11.15.2 Merck Business Overview
11.15.3 Merck Polycystic Ovary Syndrome Introduction
11.15.4 Merck Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.15.5 Merck Recent Development
11.16 Millendo Therapeutics
11.16.1 Millendo Therapeutics Company Detail
11.16.2 Millendo Therapeutics Business Overview
11.16.3 Millendo Therapeutics Polycystic Ovary Syndrome Introduction
11.16.4 Millendo Therapeutics Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.16.5 Millendo Therapeutics Recent Development
11.17 MyOva
11.17.1 MyOva Company Detail
11.17.2 MyOva Business Overview
11.17.3 MyOva Polycystic Ovary Syndrome Introduction
11.17.4 MyOva Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.17.5 MyOva Recent Development
11.18 Novartis
11.18.1 Novartis Company Detail
11.18.2 Novartis Business Overview
11.18.3 Novartis Polycystic Ovary Syndrome Introduction
11.18.4 Novartis Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.18.5 Novartis Recent Development
11.19 Ogeda
11.19.1 Ogeda Company Detail
11.19.2 Ogeda Business Overview
11.19.3 Ogeda Polycystic Ovary Syndrome Introduction
11.19.4 Ogeda Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.19.5 Ogeda Recent Development
11.20 PCOS Diva
11.20.1 PCOS Diva Company Detail
11.20.2 PCOS Diva Business Overview
11.20.3 PCOS Diva Polycystic Ovary Syndrome Introduction
11.20.4 PCOS Diva Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.20.5 PCOS Diva Recent Development
11.21 Pharmasure
11.21.1 Pharmasure Company Detail
11.21.2 Pharmasure Business Overview
11.21.3 Pharmasure Polycystic Ovary Syndrome Introduction
11.21.4 Pharmasure Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.21.5 Pharmasure Recent Development
11.22 Salveo Lifecare
11.22.1 Salveo Lifecare Company Detail
11.22.2 Salveo Lifecare Business Overview
11.22.3 Salveo Lifecare Polycystic Ovary Syndrome Introduction
11.22.4 Salveo Lifecare Revenue in Polycystic Ovary Syndrome Business (2018-2023)
11.22.5 Salveo Lifecare Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Polycystic Ovary Syndrome Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Diuretics
Table 3. Key Players of Insulin sensitizing agents
Table 4. Key Players of Antiandrogens
Table 5. Key Players of Anti-depressants
Table 6. Key Players of Ornithine decarboxylase inhibitors
Table 7. Global Polycystic Ovary Syndrome Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Polycystic Ovary Syndrome Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Polycystic Ovary Syndrome Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Polycystic Ovary Syndrome Market Share by Region (2018-2023)
Table 11. Global Polycystic Ovary Syndrome Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Polycystic Ovary Syndrome Market Share by Region (2024-2033)
Table 13. Polycystic Ovary Syndrome Market Trends
Table 14. Polycystic Ovary Syndrome Market Drivers
Table 15. Polycystic Ovary Syndrome Market Challenges
Table 16. Polycystic Ovary Syndrome Market Restraints
Table 17. Global Polycystic Ovary Syndrome Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Polycystic Ovary Syndrome Market Share by Players (2018-2023)
Table 19. Global Top Polycystic Ovary Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polycystic Ovary Syndrome as of 2022)
Table 20. Ranking of Global Top Polycystic Ovary Syndrome Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Polycystic Ovary Syndrome Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Polycystic Ovary Syndrome Product Solution and Service
Table 24. Date of Enter into Polycystic Ovary Syndrome Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Polycystic Ovary Syndrome Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Polycystic Ovary Syndrome Revenue Market Share by Type (2018-2023)
Table 28. Global Polycystic Ovary Syndrome Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Polycystic Ovary Syndrome Revenue Market Share by Type (2024-2033)
Table 30. Global Polycystic Ovary Syndrome Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Polycystic Ovary Syndrome Revenue Market Share by Application (2018-2023)
Table 32. Global Polycystic Ovary Syndrome Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Polycystic Ovary Syndrome Revenue Market Share by Application (2024-2033)
Table 34. North America Polycystic Ovary Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Polycystic Ovary Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Polycystic Ovary Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Polycystic Ovary Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Polycystic Ovary Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Polycystic Ovary Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Polycystic Ovary Syndrome Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Polycystic Ovary Syndrome Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Polycystic Ovary Syndrome Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Polycystic Ovary Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Polycystic Ovary Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Polycystic Ovary Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Polycystic Ovary Syndrome Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Polycystic Ovary Syndrome Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Polycystic Ovary Syndrome Market Size by Country (2024-2033) & (US$ Million)
Table 49. Abbott Laboratories Company Detail
Table 50. Abbott Laboratories Business Overview
Table 51. Abbott Laboratories Polycystic Ovary Syndrome Product
Table 52. Abbott Laboratories Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 53. Abbott Laboratories Recent Development
Table 54. Addex therapeutics Company Detail
Table 55. Addex therapeutics Business Overview
Table 56. Addex therapeutics Polycystic Ovary Syndrome Product
Table 57. Addex therapeutics Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 58. Addex therapeutics Recent Development
Table 59. Himalaya Company Detail
Table 60. Himalaya Business Overview
Table 61. Himalaya Polycystic Ovary Syndrome Product
Table 62. Himalaya Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 63. Himalaya Recent Development
Table 64. Astellas Pharma Company Detail
Table 65. Astellas Pharma Business Overview
Table 66. Astellas Pharma Polycystic Ovary Syndrome Product
Table 67. Astellas Pharma Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 68. Astellas Pharma Recent Development
Table 69. AstraZeneca Company Detail
Table 70. AstraZeneca Business Overview
Table 71. AstraZeneca Polycystic Ovary Syndrome Product
Table 72. AstraZeneca Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 73. AstraZeneca Recent Development
Table 74. Ava Science Company Detail
Table 75. Ava Science Business Overview
Table 76. Ava Science Polycystic Ovary Syndrome Product
Table 77. Ava Science Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 78. Ava Science Recent Development
Table 79. Bayer Company Detail
Table 80. Bayer Business Overview
Table 81. Bayer Polycystic Ovary Syndrome Product
Table 82. Bayer Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 83. Bayer Recent Development
Table 84. Bristol-Myers Squibb Company Detail
Table 85. Bristol-Myers Squibb Business Overview
Table 86. Bristol-Myers Squibb Polycystic Ovary Syndrome Product
Table 87. Bristol-Myers Squibb Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 88. Bristol-Myers Squibb Recent Development
Table 89. Theralogix Company Detail
Table 90. Theralogix Business Overview
Table 91. Theralogix Polycystic Ovary Syndrome Product
Table 92. Theralogix Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 93. Theralogix Recent Development
Table 94. Ferring Pharmaceuticals Company Detail
Table 95. Ferring Pharmaceuticals Business Overview
Table 96. Ferring Pharmaceuticals Polycystic Ovary Syndrome Product
Table 97. Ferring Pharmaceuticals Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 98. Ferring Pharmaceuticals Recent Development
Table 99. Teva Pharmaceutical Company Detail
Table 100. Teva Pharmaceutical Business Overview
Table 101. Teva Pharmaceutical Polycystic Ovary Syndrome Product
Table 102. Teva Pharmaceutical Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 103. Teva Pharmaceutical Recent Development
Table 104. GSK Company Detail
Table 105. GSK Business Overview
Table 106. GSK Polycystic Ovary Syndrome Product
Table 107. GSK Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 108. GSK Recent Development
Table 109. Sneha Natura Company Detail
Table 110. Sneha Natura Business Overview
Table 111. Sneha Natura Polycystic Ovary Syndrome Product
Table 112. Sneha Natura Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 113. Sneha Natura Recent Development
Table 114. Jarrow Formulas Company Detail
Table 115. Jarrow Formulas Business Overview
Table 116. Jarrow Formulas Polycystic Ovary Syndrome Product
Table 117. Jarrow Formulas Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 118. Jarrow Formulas Recent Development
Table 119. Merck Company Detail
Table 120. Merck Business Overview
Table 121. Merck Polycystic Ovary Syndrome Product
Table 122. Merck Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 123. Merck Recent Development
Table 124. Millendo Therapeutics Company Detail
Table 125. Millendo Therapeutics Business Overview
Table 126. Millendo Therapeutics Polycystic Ovary Syndrome Product
Table 127. Millendo Therapeutics Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 128. Millendo Therapeutics Recent Development
Table 129. MyOva Company Detail
Table 130. MyOva Business Overview
Table 131. MyOva Polycystic Ovary Syndrome Product
Table 132. MyOva Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 133. MyOva Recent Development
Table 134. Novartis Company Detail
Table 135. Novartis Business Overview
Table 136. Novartis Polycystic Ovary Syndrome Product
Table 137. Novartis Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 138. Novartis Recent Development
Table 139. Ogeda Company Detail
Table 140. Ogeda Business Overview
Table 141. Ogeda Polycystic Ovary Syndrome Product
Table 142. Ogeda Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 143. Ogeda Recent Development
Table 144. PCOS Diva Company Detail
Table 145. PCOS Diva Business Overview
Table 146. PCOS Diva Polycystic Ovary Syndrome Product
Table 147. PCOS Diva Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 148. PCOS Diva Recent Development
Table 149. Pharmasure Company Detail
Table 150. Pharmasure Business Overview
Table 151. Pharmasure Polycystic Ovary Syndrome Product
Table 152. Pharmasure Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 153. Pharmasure Recent Development
Table 154. Salveo Lifecare Company Detail
Table 155. Salveo Lifecare Business Overview
Table 156. Salveo Lifecare Polycystic Ovary Syndrome Product
Table 157. Salveo Lifecare Revenue in Polycystic Ovary Syndrome Business (2018-2023) & (US$ Million)
Table 158. Salveo Lifecare Recent Development
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Polycystic Ovary Syndrome Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Polycystic Ovary Syndrome Market Share by Type: 2022 VS 2033
Figure 3. Diuretics Features
Figure 4. Insulin sensitizing agents Features
Figure 5. Antiandrogens Features
Figure 6. Anti-depressants Features
Figure 7. Ornithine decarboxylase inhibitors Features
Figure 8. Global Polycystic Ovary Syndrome Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Polycystic Ovary Syndrome Market Share by Application: 2022 VS 2033
Figure 10. Hospital pharmacies Case Studies
Figure 11. Drug stores Case Studies
Figure 12. Retail pharmacies Case Studies
Figure 13. Polycystic Ovary Syndrome Report Years Considered
Figure 14. Global Polycystic Ovary Syndrome Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Polycystic Ovary Syndrome Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Polycystic Ovary Syndrome Market Share by Region: 2022 VS 2033
Figure 17. Global Polycystic Ovary Syndrome Market Share by Players in 2022
Figure 18. Global Top Polycystic Ovary Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Polycystic Ovary Syndrome as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Polycystic Ovary Syndrome Revenue in 2022
Figure 20. North America Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Polycystic Ovary Syndrome Market Share by Country (2018-2033)
Figure 22. United States Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Polycystic Ovary Syndrome Market Share by Country (2018-2033)
Figure 26. Germany Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Polycystic Ovary Syndrome Market Share by Region (2018-2033)
Figure 34. China Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Polycystic Ovary Syndrome Market Share by Country (2018-2033)
Figure 42. Mexico Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Polycystic Ovary Syndrome Market Share by Country (2018-2033)
Figure 46. Turkey Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Polycystic Ovary Syndrome Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Abbott Laboratories Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 49. Addex therapeutics Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 50. Himalaya Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 51. Astellas Pharma Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 52. AstraZeneca Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 53. Ava Science Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 54. Bayer Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 55. Bristol-Myers Squibb Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 56. Theralogix Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 57. Ferring Pharmaceuticals Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 58. Teva Pharmaceutical Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 59. GSK Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 60. Sneha Natura Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 61. Jarrow Formulas Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 62. Merck Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 63. Millendo Therapeutics Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 64. MyOva Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 65. Novartis Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 66. Ogeda Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 67. PCOS Diva Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 68. Pharmasure Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 69. Salveo Lifecare Revenue Growth Rate in Polycystic Ovary Syndrome Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed